Antisense oligonucleotides against TNFR1 prevent toxicity of TNF/IFNγ treatment in mouse tumor models. (Q49097159)

18 February 2018

title

Antisense oligonucleotides against TNFR1 prevent toxicity of TNF/IFNγ treatment in mouse tumor models. (English)

1 reference

18 February 2018

main subject

TNF

0 references

author

Roosmarijn Vandenbroucke

2

1 reference

18 February 2018

author name string

Filip Van Hauwermeiren

1

1 reference

18 February 2018

Lynda Grine

3

1 reference

18 February 2018

Leen Puimège

4

1 reference

18 February 2018

Elien Van Wonterghem

5

1 reference

18 February 2018

Hong Zhang

6

1 reference

18 February 2018

Claude Libert

7

1 reference

18 February 2018

language of work or name

English

0 references

publication date

13 January 2014

1 reference

18 February 2018

International Journal of Cancer

published in

1 reference

18 February 2018

volume

135

1 reference

18 February 2018

issue

3

1 reference

18 February 2018

page(s)

742-750

1 reference

18 February 2018

The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease

cites work

1 reference

In vivo anti-tumour activity of recombinant human and murine TNF, alone and in combination with murine IFN-gamma, on a syngeneic murine melanoma.

21 January 2018

1 reference

Shock and tissue injury induced by recombinant human cachectin

21 January 2018

1 reference

Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma

21 January 2018

1 reference

NF-kappaB: linking inflammation and immunity to cancer development and progression

21 January 2018

1 reference

Safe TNF-based antitumor therapy following p55TNFR reduction in intestinal epithelium

21 January 2018

1 reference

TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors

21 January 2018

1 reference

Preclinical investigation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: phase I evaluation

21 January 2018

1 reference

Improving TNF as a cancer therapeutic: tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects

21 January 2018

1 reference

Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).

21 January 2018

1 reference

Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy

21 January 2018

1 reference

IL-17 produced by Paneth cells drives TNF-induced shock

21 January 2018

1 reference

RIP kinase-dependent necrosis drives lethal systemic inflammatory response syndrome

21 January 2018

1 reference

Type I interferon drives tumor necrosis factor-induced lethal shock

21 January 2018

1 reference

Two tumour necrosis factor receptors: structure and function.

21 January 2018

1 reference

Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes

21 January 2018

1 reference

Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature

21 January 2018

1 reference

Characterization of fully 2'-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity

21 January 2018

1 reference

RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform

21 January 2018

1 reference

An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study

21 January 2018

1 reference

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Antisense therapy for cancer

21 January 2018

1 reference

Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas

21 January 2018

1 reference

Antisense oligonucleotide inhibition of tumor necrosis factor receptor 1 protects the liver from radiation-induced apoptosis.

21 January 2018

1 reference

Protection against TNF-induced lethal shock by soluble guanylate cyclase inhibition requires functional inducible nitric oxide synthase.

21 January 2018

1 reference

Crystal structure and improved antisense properties of 2'-O-(2-methoxyethyl)-RNA

21 January 2018

1 reference

Role of RNase H in hybrid-arrested translation by antisense oligonucleotides

21 January 2018

1 reference

Knocking down barriers: advances in siRNA delivery

21 January 2018

1 reference

Antisense oligonucleotide blockade of tumor necrosis factor-alpha in two murine models of colitis

21 January 2018

1 reference

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.28704

1 reference

18 February 2018

PubMed ID

24382818

1 reference

18 February 2018